Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering's diagnostic sales beat expectations:

This article was originally published in Clinica

Executive Summary

German company Schering had full-year diagnostic sales of Euro1,040 million ($1,013 million), up 18% and "far ahead of expectations", the company said. Berlin-based Schering attributed the good result to a substantial growth in volume sales, as well as the recovery of the Asian currencies and relatively stable prices in Japan. X-ray contrast media sales increased 17% to Euro646 million, while sales of Magnevist, a contrast media for MRI, rose 18% to Euro233 million. During the year, the company expanded into radiopharmaceuticals with the acquisition of US company Diatide and CIS of France.

You may also be interested in...



Biogen Value-Based Contract Links Patient-Reported Outcomes To MS Drug Reimbursement

Biogen value-based contract with UPMC Health Plan ties payments to patient-reported outcomes for Tecfidera and Avonex. The company may seek something similar for Vumerity.

Outcomes-Based Contracts May Rely More On Patient-Reported Results

As interest in immune/inflammatory disease increases and savings achieved dip, payer focus on patient-reported outcomes for contracts reflects shift in focus, Avalere survey suggests.

Industry Advocacy Group Goes Global After Device Tax Repeal

After an eleventh-hour win last year that saw Congress repeal the medical device excise tax, AdvaMed is going more global. CEO Scott Whitaker sat down with Medtech Insight for a lengthy chat about what the lobby group will focus on in 2020, including reimbursement challenges, the upcoming medical device user-fee negotiations, and negotiations with governments that are key to the industry ecosystem.

Topics

UsernamePublicRestriction

Register

MT075731

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel